The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | ASCO 2020: BiTEs in multiple myeloma
Thomas Martin, MD, of the Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, reflects on studies investigating the use of BiTEs in relapsed/refractory myeloma treatment, a patient population with an unment need. Presented in ASCO 2020, Dr Martin highlights teclistamab, BCMA x CD3 bispecific antibody investigated in a Phase I dose-escalation study. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
